Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being done to see if an experimental drug called recombinant interleukin-21 (rIL-21) when given to patients with stage 4 malignant melanoma or stage 4 kidney cancer is safe and has any effect on these types of cancers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ZymoGenetics

Criteria

Inclusion Criteria:

• 18 years and older with stage 4 metastatic malignant melanoma or stage 4 metastatic kidney cancer

• ECOG status of 0 or 1

• Patients must have adequate liver, kidney and bone marrow function

Exclusion Criteria:

• Known ocular melanoma

• Suspected or confirmed brain metastases

• Patient cannot have had a bone marrow transplant